论文部分内容阅读
目的:探讨阿托伐他汀联合替罗非班对急性心肌梗死的临床治疗效果并进行分析。方法:抽取自2014年10月至2016年10月期间收治入院的急性心肌梗死患者,并选取其中50例作为本次的研究对象。结果:参照组与研究组的临床治疗疗效比较,研究组显著优于参照组,P<0.05,有临床统计学意义;另外,两组患者的不良反应发生情况比较,研究组显著低于参照组,P<0.05,有临床统计学意义。结论:应用阿托伐他汀联合替罗非班对急性心肌梗死的临床治疗效果显著,而且不良反应发生情况低,不良反应率低,安全性高,值得在临床上做进一步的推广与应用。
Objective: To investigate the clinical effect of atorvastatin combined with tirofiban on acute myocardial infarction and to analyze the results. Methods: Patients with acute myocardial infarction admitted to hospital from October 2014 to October 2016 were selected and 50 of them were selected as the study subjects. Results: Compared with the clinical curative effect of the reference group and the research group, the study group was significantly better than the reference group, P <0.05, with statistical significance; in addition, the two groups of patients with adverse reactions, the study group was significantly lower than the reference group , P <0.05, with clinical significance. Conclusion: The combination of atorvastatin and tirofiban has a significant effect on clinical treatment of acute myocardial infarction. Moreover, the incidence of adverse reactions is low, the rate of adverse reactions is low, and the safety is high. Therefore, it is worth further clinical application.